CoChat

PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia

Open access
Gawel, Justyna M., Shouksmith, Andrew E., Raouf, Yasir S., Nawar, Nabanita, Toutah, Krimo, Bukhari, Shazreh, Manaswiyoungkul, Pimyupa, Olaoye, Olasunkanmi O., Israelian, Johan, Radu, Tudor B., Cabral, Aaron D., Sina, Diana, Sedighi, Abootaleb, de Araujo, Elvin D., Gunning, Patrick T. · 2020 · European Journal of Medicinal Chemistry
Cited by 41

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as critical druggable targets, amenable to small molecule intervention. While efficacious, current approaches using non-selective HDAC inhibitors (HDACi) have been shown to cause a range of undesirable clinical toxicities. To circumvent this, recent efforts have focused on the design of highly selective HDACi as a novel therapeutic strategy. Beyond roles in regulating transcription, the unique HDAC6 (with two catalytic domains) regulates the deacetylation of α-tubulin; promoting growth factor-controlled cell motility, cell division, and metastatic hallmarks. Recent studies have linked aberrant HDAC6 function in various hematological cancers including acute myeloid leukaemia and multiple myeloma. Herein, we report the discovery, in vitro characterization, and biological evaluation of PTG-0861 (JG-265), a novel HDAC6-selective inhibitor with strong isozyme-selectivity (∼36× ) and low nanomolar potency (IC50 = 5.92 nM) against HDAC6. This selectivity profile was rationalized via in silico docking studies and also observed in cellulo through cellular target engagement. Moreover, PTG-0861 achieved relevant potency against several blood cancer cell lines (e.g. MV4-11, MM1S), whilst showing limited cytotoxicity against non-malignant cells (e.g. NHF, HUVEC) and CD-1 mice. In examining compound stability and cellular permeability, PTG-0861 revealed a promising in vitro pharmacokinetic (PK) profile. Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (∼4× more selective than current clinical standards - citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematological cancer cells with a promising safety profile and in vitro PK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2020.112411

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 41

Metadata

Authors
Gawel, J. M., Shouksmith, A. E., Raouf, Y. S., Nawar, N., Toutah, K., Bukhari, S., Manaswiyoungkul, P., Olaoye, O. O., Israelian, J., Radu, T. B., Cabral, A. D., Sina, D., Sedighi, A., de Araujo, E. D., & Gunning, P. T.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2020-09
Volume
201
Pages
112411
ISSN
0223-5234 (ISSN-L)
OpenAlex
W3034152397
Cited by
41
References
8
FWCI
1.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. https://app.cochat.ai/papers/10.1016/j.ejmech.2020.112411
The paper
Gawel, J. M., Shouksmith, A. E., Raouf, Y. S., Nawar, N., Toutah, K., Bukhari, S., Manaswiyoungkul, P., Olaoye, O. O., Israelian, J., Radu, T. B., Cabral, A. D., Sina, D., Sedighi, A., de Araujo, E. D., & Gunning, P. T. (2020). PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2020.112411

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.